Connecticut just made a quiet but significant move in the march toward mainstream psychedelic medicine. On March 3, 2026, the state legislature’s Joint Committee on Public Health approved Senate Bill 191, legislation that expands the state’s existing psychedelic-assisted therapy pilot program, a move that ripples across the broader landscape of plant medicine and cannabis reform.
For cannabis industry stakeholders, operators, and investors, this development is worth paying close attention to. States that lead on psychedelic research often lead on cannabis policy, and the arguments being made in Hartford today mirror those made about medical marijuana a decade ago.
What Does SB 191 Actually Do?
Connecticut’s psychedelic therapy program was originally created to serve military veterans and first responders populations experiencing alarming rates of PTSD and suicide. The program allowed those individuals to participate in clinical trials involving psilocybin (the active compound in “magic mushrooms”) and MDMA as therapeutic agents under medical supervision.
SB 191 makes three critical changes. First, it expands eligibility to any adult aged 18 or older who meets the clinical criteria established by the institutional review board of the administering medical school, a direct response to requests from clinicians and researchers who argued the original restrictions were too narrow. Second, it removes the sunset clause that would have ended the program automatically if psilocybin or MDMA received DEA or FDA approval, ensuring Connecticut’s research infrastructure remains intact regardless of federal action. Third, it aligns program operations with FDA-approved research frameworks, maintaining scientific rigor while positioning the state to act quickly if federal approval materializes.
Sen. Saud Anwar (D), chair of the Public Health Committee, explained the rationale plainly: “There’s a chance that psychedelic medications for this purpose will be approved by the FDA, which makes the research study stop if you don’t make a change in the language. So that’s the main purpose of this.”
The FDA Angle: Why Now?
The timing of SB 191 is no accident. The FDA has been under significant pressure to evaluate MDMA-assisted therapy for PTSD treatment. MAPS (the Multidisciplinary Association for Psychedelic Studies) has spent decades conducting Phase 3 clinical trials, and psilocybin research at institutions like the Johns Hopkins Center for Psychedelic and Consciousness Research has generated compelling evidence that federal regulators can no longer ignore.
Connecticut lawmakers are essentially future-proofing their program. Without removing the sunset clause, an FDA approval, which many in the field now consider a matter of “when” rather than “if,” would have dismantled the state’s entire research infrastructure at exactly the moment it would have become most valuable.
A Pattern of Progressive Policy in Connecticut
This isn’t Connecticut’s first rodeo when it comes to psychedelic reform. The full House of Representatives passed a psilocybin decriminalization bill in 2025, and the state has now attempted to decriminalize psilocybin in three consecutive legislative sessions, the hallmark of a policy whose moment is arriving. Governor Ned Lamont also signed a sweeping budget bill in 2022 that included provisions establishing the original psychedelic treatment program, demonstrating executive-level openness to the therapeutic model even if full decriminalization has remained politically complicated.
What This Means for Cannabis Operators and Investors
The cannabis industry has a front-row seat to watch how psychedelic reform unfolds because cannabis blazed the trail. The same advocacy infrastructure, the same patient-first framing, and the same “research first, regulate later” strategy that moved cannabis from Schedule I curiosity to a multi-billion dollar industry is now being deployed for psychedelics.
Regulatory convergence is coming. As more states integrate psychedelic therapy programs, the frameworks being built now will influence how cannabis and psychedelics are governed together. Organizations like the National Cannabis Industry Association (NCIA) and the Drug Policy Alliance are already tracking the intersection of these policy streams, and operators who understand both landscapes will be positioned to expand as the broader plant medicine market evolves.
Consumer sentiment is also shifting. An estimated 10 million U.S. adults microdosed psychedelics last year. This consumer base has significant overlap with cannabis consumers educated, health-conscious, and increasingly open to plant-based wellness solutions. Dispensaries and cannabis retailers who understand this crossover customer are building long-term loyalty.
Connecticut’s Dual-Track Approach
Notably, Connecticut lawmakers are simultaneously advancing legislation to allow medical cannabis use in hospitals, nursing homes, and hospices, a bill also moving this session. This dual-track approach signals a maturing understanding among state legislators that plant medicine reform is about patient access and medical autonomy, not just recreational freedom.
The Bottom Line
Connecticut’s approval of SB 191 is a measured but meaningful step forward in the normalization of psychedelic-assisted therapy. By expanding eligibility, removing the sunset clause, and aligning with FDA research standards, Connecticut is positioning itself as a model for other states watching the federal landscape evolve.
The same political momentum, the same patient advocacy, and the same science-forward arguments that won cannabis legalization across 24 states are now reshaping the conversation around psychedelics. Connecticut is listening. For cannabis operators, the message is clear: the plant medicine space is expanding, and staying ahead of that curve starts with understanding where policy is heading. Follow ongoing coverage at Marijuana Moment and MJBizDaily to stay current as this legislation advances.
